Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Memorial Göztepe Breast Cancer Center – Medical Oncology Quality Standards and Flowchart

Memorial Göztepe Breast Cancer Center – Medical Oncology Quality Standards and Flowchart
In this article

A roadmap aligned with ECIBC (European Quality Assurance for Breast Cancer Services) – from establishment to accreditation, step by step

Quality, Speed, and Empathy in One Center

As we design our breast cancer center with the goal of international accreditation , it is critical that the medical oncology unit's processes, measurement, and patient experience follow a standardized, traceable, audit-ready structure. This work adapts ECIBC requirements to the realities of Memorial Göztepe and brings together SOPs that align teams, measurable KPIs, a patient-centered PROMs workflow, and data governance under one roof.

  • Purpose: To define, measure, and continuously improve quality in medical oncology.
  • Scope: The diagnosis–treatment interface, systemic treatment standards, time targets (lead-time), medication safety, fertility, pain, complementary medicine, PROMs, and palliative care/rehabilitation integration.
  • Our approach: the "Process + Indicator + Audit Evidence" triad. Every standard has a corresponding EMR entry and a measurable KPI.

📚 Glossary (Expanded)

  • ECIBC (European Commission Initiative on Breast Cancer): the European Commission's quality assurance framework and guideline set for breast cancer services.
  • Accreditation: a formal approval process in which an independent body certifies that the center meets defined international quality standards.
  • MDM (MultiDisciplinary Meeting, multidisciplinary meeting): a platform for joint case-based decisions by disciplines such as Surgery, Medical Oncology, Radiation Oncology, Radiology, Pathology, Psycho-oncology, and Nursing.
  • EMR (Electronic Medical Record): electronic health record
  • SOP (Standard Operating Procedure): a version-controlled standard operating procedure describing step by step how a particular process is carried out.
  • KPI (Key Performance Indicator): indicators measuring clinical or operational performance; e.g., the proportion with an interval of ≤56 days from surgery to adjuvant chemotherapy.
  • Audit: planned review of defined indicators and processes; findings may trigger a CAPA process.
  • CAPA (Corrective and Preventive Action): the set of corrective and preventive actions planned through root cause analysis when a deviation or nonconformity occurs.
  • PROMs (Patient Reported Outcome Measures): patient-reported quality-of-life, symptom, and function scores; e.g., EORTC QLQ-C30, BR23, FACT-ES.
  • PREMs (Patient Reported Experience Measures): questionnaire sets measuring patients' experiences of care (satisfaction, communication, information sharing, etc.).
  • Lead-time: the targeted maximum interval between two critical steps; e.g., pathology report → first treatment ≤28 days.
  • TNBC / HER2+ / ER / PR: biological tumor subtypes; key determinants of treatment strategy.
  • Anti-HER2 therapy: targeted treatments used in HER2-positive cases (such as trastuzumab and pertuzumab).
  • Neoadjuvant therapy: systemic treatment given before surgery (chemotherapy, immunotherapy, or targeted agents).
  • Adjuvant therapy: supportive systemic treatment given after surgery to reduce recurrence risk.
  • Audit-ready: ready for inspection; a process in which all relevant SOPs, evidence, data, and records are fully documented.
  • RACI: a responsibility matrix model; Responsible (does the work), Accountable (owns the outcome), Consulted (provides input), Informed (is kept informed).
  • EF (Ejection Fraction): an indicator of cardiac function, monitored regularly in patients receiving anti-HER2 therapy.
  • CTCAE (Common Terminology Criteria for Adverse Events): the standard classification system for toxicity and adverse effects.
  • Fertility counseling: information and referral services provided before systemic treatment to preserve reproductive potential.

The Memorial approach: clinical excellence + patient experience

We build clinical excellence on multidisciplinary board discipline, prompt, evidence-based treatment initiation and toxicity management . We combine this with patient experience and outcome measures (PROMs) and manage it within a sustainable quality cycle (Plan–Do–Check–Act).

  • Transparent measurement: time targets and compliance rates are tracked on a monthly dashboard.
  • Integration: a single workflow across Medical Oncology – Surgery – Pathology – Radiation Oncology. Palliative care and rehabilitation are integrated early when needed.
  • Data and ethics: data governance policies covering privacy, accuracy, clinical decision support, and audit-ready evidence files.

SECTION 1: Medical Oncology Quality Standards (SOPs)

1.1 💊 Medication Safety (SOP-ONC-001)

Purpose: to ensure error-free, safe prescribing, preparation, storage, administration, and waste management of cytotoxic and targeted drugs.

Scope: outpatient and inpatient chemotherapy/IO administration, pre-treatment and concomitant supportive treatments, drug interactions, and emergency toxicity management.

Steps

  1. EMR prescription entry: dose calculation (BSA/renal/hepatic), drug interaction checking and dual approval.
  2. Pharmacy preparation: closed-system transfer device (if available), labeling/verification, stability, and storage conditions.
  3. Administration: patient identity verification, venous access suitability, premedication, observation during administration.
  4. Waste and spill management: spill kit, leak protocol, trained staff.
  5. Pharmacovigilance: CTCAE adverse effect recording, serious incident reporting, root cause analysis, and CAPA.
Responsible staff: oncology pharmacist, chemotherapy nurse, responsible medical oncologist, infection control & occupational health team.
EMR Fields: prescription (regimen, cycle, dose), premedication, drug–drug interaction checkbox, administration time, CTCAE record, incident report.
KPI: prescription double-check rate ≥99%; complete CTCAE recording ≥95%; CAPA completion in serious incidents within ≤30 days ≥95%.
Audit Evidence: SOP-ONC-001 version, training lists, prescription and interaction printouts from 30 randomly selected records, spill drill records.
Terms: Double-check (verification by two people), CTCAE (common toxicity criteria), CAPA (corrective/preventive action).

1.2 🧬 Fertility Preservation (SOP-ONC-002)

Purpose: to provide systematic, timely fertility counseling before treatment for patients of reproductive age.

Scope: GnRH analogs, ovarian/embryo/oocyte cryopreservation, sperm cryopreservation in men, informed consent.

  1. Eligibility screening (age, planned regimen, family plans) and counseling at the first visit.
  2. An appointment with a fertility center within 48 hours.
  3. Consent, cost information, and a workflow preventing treatment delays.
  4. Initiation of a GnRH analog (if indicated) and coordination with planned systemic treatment.
EMR Fields: fertility counseling checkbox, referral date, GnRH prescription, consent form, feedback note.
KPI: counseling rate in eligible patients ≥90%; referral for an appointment within ≤48 hours ≥90%.
Audit Evidence: list of eligible patients in a 6-month cohort, referral intervals, consent files.

1.3 🥗 Nutrition & Physical Activity (SOP-ONC-003)

Purpose: to manage weight, muscle mass, fatigue, and metabolic risks during treatment; to improve quality of life.

Scope: NRS-2002/PG-SGA screening, a personalized diet program, an exercise prescription (e.g., 150 min/week at moderate intensity).

  • At the first visit, nutrition screening, and a dietitian appointment within 7 days for at-risk patients.
  • Exercise prescription: training type, duration, intensity; upper limb progression if there is lymphedema risk.
  • Monthly monitoring of weight/BMI/unintentional weight loss; enteral support when needed.
EMR Fields: NRS/PG-SGA score, diet plan, exercise prescription, follow-up notes.
KPI: Dietitian access within 7 days for at-risk patients ≥90%; exercise adherence for ≥8 weeks ≥70%.

1.4 🩹 Pain Management (SOP-ONC-004)

Purpose: systematic pain screening at every visit and appropriate palliative care/pain medicine management.

Scope: VAS/NRS pain scale, episodic pain, opioid titration, constipation prophylaxis, BTcP management.

  • VAS/NRS at every visit; if ≥4 , palliative consultation and a pharmacological/nonpharmacological plan.
  • Opioid education, adverse effect management, home monitoring instructions.
EMR Fields: VAS/NRS score, analgesic plan, palliative referral date, adverse effect note.
KPI: Pain score recording ≥95%; palliative assessment within ≤7 days for VAS≥4 ≥90%.

1.5 🌿 Complementary/Integrative Medicine (SOP-ONC-005)

Purpose: to prevent potential interactions/harms from herbal products and supplements; to ensure documentation and counseling.

  • Ask about "supplements/herbal products" at the first visit and every cycle.
  • Interaction warning list; for high-risk combinations, a written warning.
KPI: Documentation of inquiry ≥95%; written warning and consent for risky interactions ≥95%.

1.6 ⏱️ Time Targets (SOP-ONC-006)

Purpose: to prevent delays in treatment access; to ensure measurable time targets are met.

  • Pathology → First treatment ≤ 28 days (≥90%).
  • Surgery → Adjuvant chemotherapy ≤ 56 days (≥80%).
  • Last chemotherapy → Radiotherapy ≤ 56 days (≥80%).
EMR Fields: pathology report date, first treatment date, surgery date, first chemotherapy date, first radiotherapy date; "reason for delay" field.
KPI: compliance rates for the three time targets (monthly dashboard, red–amber–green).
Audit Evidence: time series, reasons for delays, action plans (CAPA).

1.7 🧪 Systemic Treatment Appropriateness (SOP-ONC-007)

Purpose: to ensure the right treatment starts at the right time according to molecular/biological subtypes.

  • TNBC stage II–III: mandatory neoadjuvant chemotherapy alert.
  • HER2+ stage II–III: neoadjuvant anti-HER2 combination alert.
  • ER+/PR+ (M0): mandatory adjuvant endocrine therapy checkbox.
  • ER− (M0): adjuvant chemotherapy appropriateness.
  • HER2+: alert to add anti-HER2 therapy.
  • M1 ER+/HER2−: preference for endocrine-based 1st-line therapy.
EMR Fields: ER/PR/HER2 result + date, MDM decision, treatment mode (neo/adj/metastatic), regimen selection, "appropriateness alert."
KPI: NACT in TNBC ≥90%; anti-HER2 in HER2+ ≥90%; endocrine therapy in ER+/PR+ ≥85%; endocrine-based 1st-line therapy in M1 ER+/HER2− ≥85%.

1.8 ❤️ Cardiac Monitoring – Anti-HER2 (SOP-ONC-008)

Purpose: to detect and manage cardiotoxicity early in patients receiving anti-HER2 therapy.

  • EF measurement: Baseline – Month 6 – Completion (more often if needed).
  • Cardiology protocol: thresholds for EF decline, further testing between doses, and criteria for delays.
EMR Fields: EF dates/values, cardiology opinion, treatment interruption/update note.
KPI: Completion rate of scheduled EF measurements ≥95%.

1.9 🦴 Bone-Modifying Agent (SOP-ONC-009)

Purpose: to reduce skeletal-related events in bone metastases and improve pain control.

  • Choice of zoledronic acid / denosumab (renal function, hypocalcemia risk, screening for osteonecrosis of the jaw).
  • Calcium–vitamin D prophylaxis; dental counseling.
EMR Fields: bone metastasis status, agent selection, creatinine/calcium, stomatology consultation, administration dates.
KPI: Agent initiation in eligible patients ≥90%; prophylaxis documentation ≥95%.

1.10 🧑‍⚕️ MDM & Biomarker Completeness (SOP-ONC-010)

Purpose: to document diagnostic clarity, complete biomarkers (ER/PR/HER2), and the MDM (multidisciplinary meeting) decision before treatment.

  • In the EMR, MDM date & decision are mandatory fields; match decision and treatment dates.
  • ER/PR/HER2 results should be 95%+ complete before treatment starts.
EMR Fields: MDM summary note, ER/PR/HER2 result & method & date, pathology report ID, treatment start date.
KPI: Biomarker completeness ≥95%; proportion with "Pathology → First treatment ≤28 days" ≥90%.
Audit Evidence: MDM attendance lists, MDM summaries, biomarker & timing checks in 30 randomly selected records.

SECTION 2: KPI Set (Definitions, Targets, Monitoring)

2.1 ⏱️ Time Targets (Lead-time KPIs)

These indicators are measured in "days" to identify delays in the care pathway from diagnosis to treatment . Each row specifies a formula, target rate, monitoring frequency, EMR field and alert threshold . Lead-time KPIs directly reflect our center's performance in speed, coordination, and accessibility.

KPI Code Definition & Formula (Numerator / Denominator) Target Monitoring EMR Fields Alert Threshold
DGN–TRT–6 (Diagnosis → First Treatment) Cases starting treatment within ≤28 days / all eligible cases ≥90% (median interval ≤28 days) Monthly pathology_date, first_treatment_date Green ≥90%, Amber 85%–89%, Red <85%
TRT–6 (Surgery → Adjuvant Chemotherapy) Patients receiving adjuvant chemotherapy within ≤56 days / cases with planned adjuvant chemotherapy ≥80% (median interval ≤56 days) Monthly surgery_date, first_chemo_date Green ≥80%, Amber 75%–79%, Red <75%
TRT–7 (Last Chemotherapy → Radiotherapy Start) Cases starting radiotherapy within ≤56 days / cases with planned radiotherapy ≥80% (median interval ≤56 days) Monthly last_chemo_date, first_rt_date Green ≥80%, Amber 75%–79%, Red <75%
📋 Exclusion note: If there is a medically planned delay (e.g., infection, wound healing, patient preference), it should be documented in the delay_reason_code field and reflected in the subindicator as a "justified delay."

2.2 🔬 Biomarker & MDM Compliance KPIs

KPI Definition & Formula Target Monitoring EMR Fields
DGN-TRT-5 – ER/PR/HER2 Completeness All invasive cases with ER+PR+HER2 reported before treatment / all invasive cases ≥95% Every 3 months ER/PR/HER2_sonuç, method, date
MDM-1 – MDM Decision Document Cases with an MDM decision before treatment / cases with first treatment planned ≥95% Monthly mdm_tarih, mdm_karar, participants

2.3 🧪 Systemic Treatment Appropriateness KPIs

KPI Definition & Formula Target Monitoring EMR Fields
TRT-SYS-1 – NACT in TNBC Stage II–III TNBC receiving NACT / TNBC (EII–III) cases ≥90% Annually alt_tip, evre, tedavi_modu=NEO
TRT-SYS-2 – Neoadjuvant Therapy in HER2+ Neoadjuvant systemic therapy in stage II–III HER2+ / HER2+ (EII–III) cases ≥90% Annually HER2, evre, tedavi_modu=NEO
TRT-SYS-4 – Endocrine Therapy in ER/PR+ Patients starting adjuvant endocrine therapy / ER and/or PR+ invasive (M0) cases ≥85% Every 6 months ER, PR, adjuvan_endokrin=evet
TRT-SYS-6 – Anti-HER2 in HER2+ Patients receiving anti-HER2 / HER2+ cases receiving (neo/adjuvant) chemotherapy ≥90% Every 6 months HER2, KT_var, anti_HER2=evet
TRT-SYS-7 – Cardiac Monitoring (Anti-HER2) Patients completing scheduled EF measurements / cases receiving anti-HER2 ≥95% Every 6 months EF0, EF6ay, EF_bit
TRT-SYS-8 – 1st-Line Endocrine Therapy in M1 ER+/HER2- Patients receiving endocrine-based 1st-line therapy / M1 ER+/HER2- cases ≥85% Annually evre=M1, ER/PR, HER2, 1_basamak=endokrin
TRT-SYS-9 – Bone-Modifying Agent Patients receiving an agent / M1 cases with bone metastases detected ≥90% Every 6 months kemik_met=evet, ajan=zoledronat/denosumab

2.4 🛡️ Safety, Support, and Patient Experience KPIs

KPI Definition & Formula Target Monitoring EMR Fields
SAFE-1 – Prescription Double-Check Double-checked prescriptions / all chemotherapy prescriptions ≥99% Monthly rx_doublecheck=evet
SAFE-2 – CTCAE Toxicity Recording Completeness Cycles with toxicity recorded using CTCAE / total cycles ≥95% Monthly ctcae_kayit=evet
SAFE-3 – CAPA Completion Time CAPA closed within ≤30 days / total CAPA ≥95% Every 3 months capa_acilis, capa_kapanis
FERT-1 – Fertility Counseling Eligible patients counseled / eligible patients ≥90% Every 6 months fertilite_kutu, sevk_tarihi
PAIN-1 – Pain Score Recording Visits with VAS/NRS documented / all visits ≥95% Monthly agri_skor
PROM-1 – PROMs Completion (C30/BR23) Patients completing forms at specified time points / patients scheduled for forms ≥70% (first year) Every 3 months prom_plan, prom_tamam
KPI dashboard (color codes): Green ≥ target, Amber = 95%–100% of target, Red <95% of target. Amber/red segments in time KPIs are also classified using the gecikme_nedeni field.

2.5 📅 Monitoring and Reporting Routine

  • Monthly dashboard: lead-time and safety KPIs (DGN-TRT-6, TRT-6, TRT-7, SAFE-1/2, PAIN-1).
  • 3-monthly quality meeting: PROM-1, CAPA performance, biomarker completeness (DGN-TRT-5).
  • 6-monthly clinical audit: systemic treatment appropriateness KPIs (TRT-SYS-1/2/4/6/7/8/9) and the Fertility KPI.
  • CAPA cycle: a corrective/preventive plan and repeat measurement within 30 days for red areas.
Suggested dashboard field names:patoloji_tarih,ilk_tedavi_tarih,cerrahi_tarih,ilk_KT_tarih,son_KT_tarih,ilk_RT_tarih,mdm_tarih,mdm_karar,ER/PR/HER2_sonuç,EF0/EF6ay/EF_bit,prom_plan/prom_tamam.

SECTION 3: Audit Checklists (Internal Audit)

3.1 ✅ Rapid Screening – Short Form (Monthly)

Purpose: rapid red/amber/green visibility for critical KPIs and immediate corrective action.

Checklist Item Measurement Target Status Justified Delay? Action (summary)
Pathology → First treatment ≤28 days (DGN-TRT-6) Started within ≤28 days / all eligible cases ≥90% ⬤ Green / Amber / Red Enter code (see 4.3) Brief note
Surgery → Adjuvant chemotherapy ≤56 days (TRT-6) Chemotherapy within ≤56 days / planned adjuvant chemotherapy ≥80% ⬤ Green / Amber / Red Enter code Brief note
Last chemotherapy → Radiotherapy ≤56 days (TRT-7) Radiotherapy within ≤56 days / cases with planned radiotherapy ≥80% ⬤ Green / Amber / Red Enter code Brief note
ER/PR/HER2 completeness (DGN-TRT-5) Completed / all invasive cases ≥95% ⬤ Green / Amber / Red — Brief note
Color thresholds: Green ≥ target, Amber = 95%–100% of target, Red <95% of target. Initiate CAPA for Amber/Red rows (see 4.4).

3.2 🗂️ Long Form – 30-Record Clinical Audit (Every 6 Months)

Purpose: detailed review of process compliance, documentation quality, and outcome measures.

Sampling Design

  • A total of 30 recordsfrom patients treated within the last 6 months.
  • Subtype quota: 8 ER+/HER2−, 8 HER2+, 8 TNBC, 6 metastatic (M1 – distribution may span subtypes).
  • Mode/pathway quota: 10 neoadjuvant, 10 adjuvant, 10 metastatic first-line.
  • Random selection + verification by the data manager using the EMR log .
Checkpoint Evidence Compliance Note
MDM decision documented before treatment starts mdm_tarih, mdm_karar ☐ Yes ☐ No —
ER/PR/HER2 results complete report ID, method, date ☐ Yes ☐ No —
Pathology → First treatment ≤28 days date fields + reason code ☐ Yes ☐ No ☐ Justified Enter code (see 4.3)
Surgery → Adjuvant chemotherapy ≤56 days date fields + reason code ☐ Yes ☐ No ☐ Justified Enter code
Last chemotherapy → Radiotherapy ≤56 days date fields + reason code ☐ Yes ☐ No ☐ Justified Enter code
Subtype-appropriate systemic treatment selected (TRT-SYS-1/2/4/6/8/9) regimen selection + alert banners ☐ Yes ☐ No —
Anti-HER2 recipients have completed scheduled EF measurements EF0 / EF6ay / EF_bit ☐ Yes ☐ No —
Fertility counseling provided to eligible patients referral date / consent ☐ Yes ☐ No ☐ Not eligible —
CTCAE toxicity records complete cycle notes ☐ Yes ☐ No —
Pain score recorded at every visit VAS/NRS field ☐ Yes ☐ No —
Complementary product use asked about and documented inquiry checkbox ☐ Yes ☐ No —

3.3 ⏳ "Justified Delay" Codes

For cases that do not meet the lead-time target, classify delays using standard codes (included in a subindicator for reporting).

Code Description Example
C01 Surgical wound healing / infection Seroma drainage, antibiotic course
C02 Patient's written preference / postponed start Family/work scheduling reason
C03 Comorbidity optimization Cardiac assessment/low EF
C04 Repeat pathology / awaiting further testing HER2 FISH confirmation
C05 Infection or acute condition COVID/pneumonia, neutropenia
EMR field:gecikme_nedeni_kod+ free-text explanation (gecikme_aciklama).

3.4 CAPA Template (Root Cause + Action)

Mandatory for Red/Amber KPI rows. 5 Whys (5 Whys) is recommended for root cause analysis.

  1. Problem Definition: (KPI name, period, extent of deviation)
  2. Impact: (patient count, risk level, process impact)
  3. Root Cause Analysis: (5 Whys, fishbone diagram reference)
  4. Corrective Action(s): (concrete steps, responsible staff, resources)
  5. Preventive Action(s): (process/SOP update, training, automation)
  6. Owner & Deadline: (responsible person/unit, completion date)
  7. Effectiveness Check: (remeasurement date, return to target)
  8. Documentation: (SOP number, training list, screenshot)
Target intervals: CAPA opening ≤7 days; closure ≤30 days; effectiveness check 30–90 days.

3.5 Audit Evidence Package – "Audit-Ready"

  • SOP folder: current SOP-ONC-001…010 versions, change history, distribution list
  • MDM records: participant lists, decision summaries, EMR screenshots
  • KPI export: monthly dashboard CSV/PDF, amber/red rows marked
  • Justified delay list: coded records + explanations
  • CAPA files: opening/closure forms, effectiveness checks
  • Cardiac monitoring file: EF reports, cardiology opinions
  • Fertility & counseling: referral/consent samples, feedback notes
  • Safety: sample CTCAE records, incident reports, spill drill minutes

3.6 🗓️ Audit Schedule & Roles

  • Monthly: short-form snapshot (lead-time + safety)
  • Every 3 Months: quality meeting (PROMs, CAPA performance, biomarkers)
  • Every 6 Months: 30-record long-form clinical audit
  • Roles: audit lead (medical oncology), data manager, pharmacist, nursing representative, quality unit
Privacy note: all output files undergo de-identify processing; access permissions and logs are retained.

SECTION 4: EMR Integration, PROMs Workflow, and Data Governance

4.1 💻 Mandatory EMR Fields & Alert Banners

For automated measurement of quality indicators, the following fields should be mandatory and work with clinical decision support alerts.

Field Name Description Type Mandatory?
patoloji_tarih Approval date of the final pathology report date Yes
ilk_tedavi_tarih Start date of the first systemic treatment date Yes
cerrahi_tarih Primary surgery date date Yes
ilk_KT_tarih Adjuvant chemotherapy start date date Yes
son_KT_tarih Final dose of adjuvant chemotherapy date Yes
ilk_RT_tarih Radiotherapy start date date Yes
ER_sonuç / PR_sonuç / HER2_sonuç Biomarker result set (+ method/date) coded Yes
mdm_tarih / mdm_karar Date and summary of the pre-MDM decision date+text Yes
tedavi_modu NEO / ADJ / M1 selection Yes
EF0 / EF6ay / EF_bit Scheduled EF measurements during anti-HER2 therapy number+date If applicable
agri_skor VAS/NRS (0–10) at every visit number Yes
prom_plan / prom_tamam PROMs schedule and completion flags date+boolean Yes
gecikme_nedeni_kod / gecikme_aciklama C01–C05 code and free text code+text If needed
Alert logic (example):
  • Pathology→First treatment:(ilk_tedavi_tarih - patoloji_tarih)>28→ "Red" + gecikme_nedeni_kod mandatory.
  • TNBC stage II–III:alt_tip=TNBC & evre in (II,III) & tedavi_modu≠NEO→ "Offer neoadjuvant therapy" alert.
  • HER2+:HER2=pozitif & KT_var=evet & anti_HER2≠evet→ "Add anti-HER2" alert.
  • Anti-HER2 EF monitoring:anti_HER2=evet & (EF0,EF6ay,EF_bit) eksik→ "Complete the EF schedule" alert.

4.2 📋 PROMs Workflow – Time Points & Feedback

Integrate patient-reported outcome measures (PROMs) into the EMR to provide real-time feedback for clinical decisions .

Time points:
  • T0 – Diagnosis: QLQ-C30 + BR23
  • T1 – Mid-Treatment: QLQ-C30 + BR23
  • T2 – End of Treatment: QLQ-C30 + BR23 (+ FACT-ES subset for those receiving hormone therapy)
  • T3 – Months 6–12: QLQ-C30 + BR23
  • T4 – Annual: QLQ-C30 + BR23 (survivorship check-up)
Outpatient feedback: PROM total scores and critical subscales (fatigue, pain, mood, sexual health) are shown using traffic lights ; red rows have quick referral buttons for "nurse education / psycho-oncology / palliative care."
EMR fields:prom_plan(T0–T4 schedule),prom_tamam(completion flag),prom_skor_json(subscale scores),prom_u_geri_bildirim(action taken).

4.3 🛡️ Data Governance – KVKK/GDPR, Access, and Audit Logs

Throughout the data lifecycle — collection → processing → storage → reporting → deletion/anonymization — KVKK/GDPR compliance and additional safeguards for clinical research are implemented.

  • Legal basis: health data are sensitive personal data; processing is based on a legitimate purpose, explicit consent, and/or medical diagnosis/treatment.
  • Data minimization principle: retain only the minimum set of fields needed for KPIs and audits; no excess data are stored.
  • Access control: role-based access (RBA): physician, pharmacist, nurse, data manager, quality team. Access logs are retained for 2 years.
  • Masking: reports/dashboard outputs do not display identity fields (name/Turkish identity number/contact details); only the hospital ID.
  • Audit log: record user, date-time, IP/request, field name, and old–new value (hash) for read/write/delete events.
  • Sharing: external sharing requires a data sharing protocol and de-identify processing.
  • Retention & deletion: archiving/anonymization after clinically required retention periods; deletion requests are recorded (within applicable limits).

4.4 📚 Terms & Best Practices

  • RBA: role-based access; authorization according to the principle of least privilege.
  • De-identify: removing identifying information; mandatory in reports and external sharing.
  • Data Minimization: data limited to the purpose; the mandatory field set for KPIs.
  • Audit-ready: an evidence package ready for inspection; SOP version + training + screenshot.

SECTION 5: Operational Implementation Plan & Accreditation

5.1 Operational Implementation Plan – The First 90 Days

Goal: establish a medical oncology-focused quality infrastructure at the Breast Cancer Center within 90 days ; activate live KPI monitoring, start the audit cycle, and become ready for the accreditation application.

A) Timeline & Milestones

  • Weeks 0–2: activate EMR fields (5.1), alert banners; publish SOP-ONC-001…010; standardize the MDM template.
  • Weeks 2–4: dashboard v1 (3.1–3.4 KPI set); pilot data testing; the first "short audit" (4.1) and CAPA training.
  • Weeks 4–8: PROMs workflow live (5.2); automated anti-HER2 EF monitoring; fertility counseling referral SLA ≤48 hours.
  • Weeks 8–12: 30-record long audit (4.2) → CAPA closure ≤30 days; "justified delay codes" report; accreditation dossier.
  • Day 90: dashboard v2 (trends + subgroup breakdowns) and "audit-ready" evidence package (4.5) complete.
Task R (Responsible) A (Accountable) C (Consulted) I (Informed) Deadline
EMR fields & alert logic Data Manager Medical Oncology Director IT, Pharmacy, Nursing Quality Unit Day 14
Dashboard v1 (live KPIs) Data Manager / IT BI Team Oncology Director Surgery, Radiation Oncology, Pathology Hospital Management Day 28
PROMs launch (C30/BR23) Nursing / Psycho-oncology Oncology Director IT, Palliative Care Quality Unit Day 45
Long audit (30 records) & CAPA Audit Lead (Oncology) Oncology Director Surgery, Radiation Oncology, Pharmacy Hospital Management Day 75 / Closure Day 90

B) Training Plan (First 8 Weeks)

  • Week 1: SOP-ONC-001…010 (medication safety, pain, fertility, time targets) – 2 hours.
  • Week 2: EMR fields & alert banners, data entry standard – 1.5 hours (hands-on).
  • Week 3: CTCAE recording, PROMs administration, patient experience – 2 hours.
  • Week 4: Audit & CAPA workshop (real case) – 2 hours.

C) Risk Register & Mitigation

  • Missing/inconsistent data: weekly data cleaning meeting; "mandatory field" checks; repeat training.
  • Lead-time deviations: surgery/radiotherapy slot coordination; real-time tracking of "justified delay" codes.
  • Low PROMs participation: SMS reminder + nurse call; outpatient kiosk.
  • Medication safety incidents: spill drills; pharmacy–nurse double-check rate ≥99%.

D) Resources & Budget (Summary)

  • BI/data development (dashboard v1–v2), EMR field and integration hours.
  • Form licensing/administration (PROMs), kiosk or tablet option.
  • Training hours (during working hours), documentation, and audit operating costs.

5.2 External Accreditation Application Checklist (Breast Cancer Center)

The dossier is completed with a medical oncology focus and a multidisciplinary contribution from surgery and radiation disciplines. The evidence below should be organized using the "audit-ready" package (4.5).

Section Required Evidence/Document Status Note
Governance & Organization Center organization chart, job descriptions, RACI table (6.1) ☐ Complete ☐ Incomplete —
MDM Processes MDM protocol, participant lists, decision summaries (2.10) ☐ Complete ☐ Incomplete —
Diagnosis & Pathology ER/PR/HER2 report completeness ≥95%; method/date fields (3.2) ☐ Complete ☐ Incomplete —
Time Targets Pathology→First treatment ≤28 days; Surgery→Adjuvant chemotherapy ≤56 days; Last chemotherapy→Radiotherapy ≤56 days (3.1) ☐ Complete ☐ Incomplete Justified delay codes (4.3)
Systemic Treatment Appropriateness TNBC, HER2+, ER/PR+ appropriateness KPIs (3.3) and alert evidence (5.1) ☐ Complete ☐ Incomplete —
Cardiac Monitoring (Anti-HER2) EF0/EF6ay/EF_bit completeness ≥95%; cardiology opinions (2.8) ☐ Complete ☐ Incomplete —
Fertility Preservation Counseling in eligible patients ≥90%; referral ≤48 hours (2.2) ☐ Complete ☐ Incomplete Consent samples
Nutrition & Exercise NRS/PG-SGA, exercise prescription, follow-up notes (2.3) ☐ Complete ☐ Incomplete —
Pain Management VAS/NRS recording ≥95%; palliative referral SLA (2.4) ☐ Complete ☐ Incomplete BTcP protocol
Complementary/Integrative Medicine Supplement inquiry ≥95%; written warning/consent (2.5) ☐ Complete ☐ Incomplete —
Medication Safety Double-check ≥99%; spill drills; CAPA closure ≤30 days (2.1) ☐ Complete ☐ Incomplete Pharmacovigilance
Bone-Modifying Agent Agent in eligible patients ≥90%; prophylaxis/dental check (2.9) ☐ Complete ☐ Incomplete —
PROMs & Patient Experience PROM completion ≥70%; traffic-light feedback (5.2) ☐ Complete ☐ Incomplete Sample questionnaires
Data Governance & Privacy KVKK/GDPR policies; access and audit logs (5.3) ☐ Complete ☐ Incomplete Anonymization
Audit & CAPA Monthly short audit, 6-monthly long audit, CAPA forms (4.1–4.4) ☐ Complete ☐ Incomplete CAPA template
Suggested Application Dossier Structure:
  • 00_Cover & Summary | 01_Governance | 02_MDM | 03_Diagnosis-Pathology | 04_Time Targets
  • 05_Systemic Appropriateness | 06_Anti-HER2 Cardiac | 07_Fertility | 08_Nutrition-Exercise
  • 09_Pain & Palliative Care | 10_Complementary | 11_Medication Safety | 12_Bone Agent
  • 13_PROMs & Experience | 14_Data Governance | 15_Audit & CAPA | 16_Appendices

5.3 Success Metrics & Monitoring Routine

  • Proportion of green KPIs: ≥80% in the first 90 days; ≥90% at month 6.
  • Lead-time medians: Pathology→First treatment ≤28 days; Surgery→Adjuvant treatment ≤56 days; Last chemotherapy→Radiotherapy ≤56 days.
  • Audit closure: CAPA opening within ≤7 days, closure within ≤30 days ≥95%.
  • PROMs participation: ≥70% in the first year (T0–T4); referral rate for red subscales ≥90%.

APPENDICES

E1. 🗂️ Field Dictionary (JSON/CSV)

Minimum field set for KPI calculations and EMR integration.

Field Description Type Mandatory Values (if any)
patoloji_tarih Final pathology approval date date Yes —
ilk_tedavi_tarih First systemic treatment date date Yes —
ER/PR/HER2_sonuç Biomarker statuses coded Yes positive/negative/…
mdm_tarih/mdm_karar MDM timing and decision summary date+text Yes —
tedavi_modu NEO/ADJ/M1 selection Yes NEO, ADJ, M1
EF0/EF6ay/EF_bit Anti-HER2 EF measurements number+date If applicable —

E2. 📈 Dashboard Color Thresholds and Alert Texts

Full configuration file

Color Thresholds:
  • Green: 100% of target or above
  • Amber: 95%–100% of target
  • Red: below 95% of target
Example Alerts:
  • lead_time_overdue: "Pathology→First treatment has exceeded 28 days. Enter a reason code (C01–C05)."
  • tnbc_no_neo: "Offer neoadjuvant systemic treatment for stage II–III TNBC."
  • her2_missing_targeted: "Anti-HER2 therapy must be added in a HER2+ case."
  • ef_missing: "Scheduled EF measurements for anti-HER2 therapy are missing."
  • prom_low_adherence: "The PROM completion rate is low. Schedule a reminder and a nurse call."

E3. CAPA Form

  1. Problem Definition – KPI, period, deviation
  2. Impact – patient count, risk level
  3. Root Cause Analysis – 5 Whys / fishbone
  4. Corrective Action(s) – step, responsible person, resources
  5. Preventive Action(s) – SOP/training/automation
  6. Deadline & Owner – completion date, responsible person
  7. Effectiveness Check – remeasurement
  8. Documentation – SOP number, training list, screenshot
Target Intervals: Opening ≤7 days; closure ≤30 days; effectiveness check 30–90 days.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Memorial Göztepe Breast Cancer Center – Medical Oncology Quality Standards and Flowchart

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy